Fig. 2: IZI1551+marizomib co-treatments are effective in 3D tumor cell spheroid models. | Cell Death & Disease

Fig. 2: IZI1551+marizomib co-treatments are effective in 3D tumor cell spheroid models.

From: Marizomib sensitizes primary glioma cells to apoptosis induced by a latest-generation TRAIL receptor agonist

Fig. 2: IZI1551+marizomib co-treatments are effective in 3D tumor cell spheroid models.

A Cell lines were cultivated as a 3D spheroid and stimulated with the indicated concentrations of IZI1551 and marizomib for 24 h. Cell viability was assessed by WST-1 assays. Data are mean values from three independent experiments. SEMs across the repeat experiments and conditions were <20%. B Synergy scores of drug combinations were determined by calculating Webb’s fractional product. C Spheroids were treated with IZI1551 (1 nM) or marizomib (80 nM) or a combination of both in the presence or absence of the pan-caspase inhibitor Q-VD-Oph (50 μM). Cell death was measured by Annexin V/PI-based flow cytometry. Data represent mean ± SEM from three independent experiments. *p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001 ****p ≤ 0.0001; one-way ANOVA followed by Tukey post hoc test.

Back to article page